Publications by authors named "Keyvan Rezai"

Claim this Profile
A
Acetalax and Bisacodyl for the Treatment of Triple-Negative Breast Cancer: A Combined Molecular and Preclinical Study.
William C Reinhold, Elisabetta Marangoni, Fathi Elloumi, Remi Montagne, Sudhir Varma, Keyvan Rezai

Cancer Res Commun· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers.
Filippo Spriano, Giulio Sartori, Jacopo Sgrignani, Laura Barnabei, Alberto J Arribas, Keyvan Rezai

Haematologica· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of an Environmental Monitoring to Assess the Practices and Control the Risk of Occupational Exposure to Cyclophosphamide in Two Sites of a French Comprehensive Cancer Center.
Alexandre Acramel, Julien Fouque, Sandy Blondeel-Gomes, Samuel Huguet, Keyvan Rezai

Ann Work Expo Health· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Grégoire Marret, Nicolas Isambert, Keyvan Rezai, Jocelyn Gal, Esma Saada-Bouzid

Invest New Drugs· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of potent dual PDK1/AurA kinase inhibitors for cancer therapy: Lead-optimization, structural insights, and ADME-Tox profile.
Simona Sestito, Andrea Bacci, Sara Chiarugi, Massimiliano Runfola, Francesca Gado, Keyvan Rezai

Eur J Med Chem· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.
Cecile Vicier, Patrick Sfumato, Nicolas Isambert, Florence Dalenc, Marie Robert, Keyvan Rezai

Eur J Cancer· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART Trial.
Francisco Bautista, Xavier Paoletti, Jonathan Rubino, Caroline Brard, Keyvan Rezai

J Clin Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II randomised study of preoperative trastuzumab alone or combined with everolimus in patients with early HER2-positive breast cancer and predictive biomarkers (RADHER trial).
Mario Campone, Thomas Bachelot, Isabelle Treilleux, Barbara Pistilli, Julia Salleron, Keyvan Rezai

Eur J Cancer· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single radio UHPLC analysis for the quality control of technetium-99m radiolabelled radiopharmaceuticals.
Camille Schmitt, Julien Fouque, Samuel Huguet, Emilie Da Costa Branquinho, Sandy Blondeel, Keyvan Rezai

Appl Radiat Isot· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Ultra-fast liquid chromatography method coupled with ultraviolet detection to quantify dimethylsulfoxide, dimethylformamide and dimethylacetamide in short half-lives radiopharmaceuticals.
Julien Fouque, Timofei Rusu, Samuel Huguet, Emilie Da Costa Branquinho, Sandy Blondeel-Gomes

J Labelled Comp Radiopharm· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I-II Open-Label Multicenter Study of Palbociclib + Vemurafenib in Metastatic Melanoma Patients: Uncovering CHEK2 as a Major Response Mechanism.
Baptiste Louveau, Matthieu Resche-Rigon, Thierry Lesimple, Laetitia Da Meda, Marc Pracht, Keyvan Rezai

Clin Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Adrenomedullin in Oncology: A Feasible Strategy With Potential as Much More Than an Alternative Anti-Angiogenic Therapy.
Ramiro Vázquez, Maria E Riveiro, Caroline Berenguer-Daizé, Anthony O'Kane, Julie Gormley, Keyvan Rezai

Front Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease.
Valentina Peta, Jianhui Zhu, David M Lubman, Samuel Huguet, Francoise Imbert-Bismutd, Keyvan Rezai

Clin Res Hepatol Gastroenterol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models.
Lucile Astorgues-Xerri, Ramiro Vázquez, Elodie Odore, Keyvan Rezai, Carmen Kahatt

Leuk Lymphoma· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epigenetic Control of Mitochondrial Fission Enables Self-Renewal of Stem-like Tumor Cells in Human Prostate Cancer.
Gianluca Civenni, Roberto Bosotti, Andrea Timpanaro, Ramiro Vàzquez, Jessica Merulla, Keyvan Rezai

Cell Metab· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP.
E Baudry, S Huguet, A L Couderc, P Chaibi, F Bret, Keyvan Rezai

Cancer Chemother Pharmacol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers.
Paul H Cottu, Jacques Bonneterre, Andrea Varga, Mario Campone, Alexandra Leary, Keyvan Rezai

PLoS One· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors.
Jeremy Lewin, Jean-Charles Soria, Anastasios Stathis, Jean-Pierre Delord, Solange Peters, Keyvan Rezai

J Clin Oncol· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance.
Chiara Tarantelli, Elena Bernasconi, Eugenio Gaudio, Luciano Cascione, Valentina Restelli, Keyvan Rezai

ESMO Open· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer.
Mathilde Guerin, Keyvan Rezai, Nicolas Isambert, Mario Campone, Aurélie Autret

Eur J Cancer· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
Ramiro Vázquez, María E Riveiro, Lucile Astorgues-Xerri, Elodie Odore, Keyvan Rezai

Oncotarget· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.
Maria E Riveiro, Lucile Astorgues-Xerri, Ramiro Vazquez, Roberta Frapolli, Ivo Kwee, Keyvan Rezai

Oncotarget· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OTX015 (MK-8628), a novel BET inhibitor, displays in vitro and in vivo antitumor effects alone and in combination with conventional therapies in glioblastoma models.
Caroline Berenguer-Daizé, Lucile Astorgues-Xerri, Elodie Odore, Mylène Cayol, Esteban Cvitkovic, Keyvan Rezai

Int J Cancer· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma.
Eugenio Gaudio, Chiara Tarantelli, Maurilio Ponzoni, Elodie Odore, Keyvan Rezai

Oncotarget· September 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
Sandy Amorim, Anastasios Stathis, Mary Gleeson, Sunil Iyengar, Valeria Magarotto, Keyvan Rezai

Lancet Haematol· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis